Status:
UNKNOWN
Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents
Lead Sponsor:
Opal Rheumatology Ltd.
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Rheumatoid Arthritis
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondyliti...
Eligibility Criteria
Inclusion
- Patients with a confirmed diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) who are being treated at a participating OPAL clinic.
Exclusion
- \-
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT03470688
Start Date
March 1 2018
End Date
December 31 2021
Last Update
March 21 2018
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Canberra Rheumatology
Canberra, Australian Capital Territory, Australia, 2601
2
Rheumatology ACT
Canberra, Australian Capital Territory, Australia, 2606
3
Susan Street Specialists Centre
Camperdown, New South Wales, Australia, 2042
4
Hills Rheumatology
Castle Hill, New South Wales, Australia, 2154